In the rapidly evolving healthcare landscape, the concept of 4P Medicine—Prevention, Prediction, Precision, and Participation—marks a transformative shift towards personalized healthcare. This approach, refined over the last 15 years, aims to revolutionize how we understand, prevent, and treat diseases by focusing on each patient’s unique needs. The recent whitepaper by Worldwide Clinical Trials highlights the profound impact of 4P Medicine on clinical development and patient care.
Researchers identify blockers of CNS effects of PD1 cancer therapy
Latest NewsGerman researchers have tracked down the causes for central nervous system side effects of cancer immunotherapies and blocked them in small animal models.
The Power of 4P Medicine in Revolutionizing Patient Care
Sponsored PublicationsIn the rapidly evolving healthcare landscape, the concept of 4P Medicine—Prevention, Prediction, Precision, and Participation—marks a transformative shift towards personalized healthcare. This approach, refined over the last 15 years, aims to revolutionize how we understand, prevent, and treat diseases by focusing on each patient’s unique needs. The recent whitepaper by Worldwide Clinical Trials highlights the profound impact of 4P Medicine on clinical development and patient care.
CATALYSER – the Start-up-Magazine 2/24
ProductsA print magazine focussing on start-ups in the life sciences! Like a catalyst, it aims to promote young companies in the life sciences with the right impulses.
Evotec SE cashes in €20m milestone
Latest NewsEvotec SE has reached a predefined milestone worth €20m in the CRO’s partnership with Bristol Myers Squibb (BMS).
Tacalyx’ extends seed capital financing
Latest NewsGlycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies.
CRISPR screen highlights genes behind T cell plasticity in autoimmunity
Latest NewsResearchers at University Hospital Hamburg-Eppendorf have laid the foundation to screen for molecules that shift Th17 cells from proinflammatory or immune-dampening mode.
GSK closes US$50m acquisition with Elsie Biotechnologies Inc
Latest NewsGSK takes over Elsie Biotechnologies in US$50m deal to boost its oligonucleotide-based drug platform and pipeline.
ITM gets equity to launch Phase III lead radiopharmaceutical ITM-11
Latest NewsITM Isotope Technologies Munich SE has raised €188m ito boost radiopharma pipeline, contract manufacturing cpacity, and launch ITM-11.
Quantro Therapeutics cashes in milestone payment from Boehringer Ingelheim
Latest NewsViennese biotech QUANTRO Therapeutics identifies small molecule targeting an onkogenic transcription factor in Boehringer Ingelheim collab.
Young biotech company recruits experienced CMO
AppointmentsAt the end of May, Dr Uwe Meya took over as Chief Medical Officer at Oxford-based SynaptixBio.